Table of Content

1 Diabetic Neuropathic Pain Drug Market Overview
1.1 Diabetic Neuropathic Pain Drug Product Overview
1.2 Diabetic Neuropathic Pain Drug Market Segment by Type
1.2.1 AZD-5213
1.2.2 Clonidine Hydrochloride
1.2.3 Duloxetine Hydrochloride DR
1.2.4 E-52862
1.2.5 Filgrastim
1.2.6 GERPOOI
1.2.7 GRC-17536
1.2.8 Others
1.3 Global Diabetic Neuropathic Pain Drug Market Size by Type
1.3.1 Global Diabetic Neuropathic Pain Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Diabetic Neuropathic Pain Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Diabetic Neuropathic Pain Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Diabetic Neuropathic Pain Drug Sales Breakdown by Type (2018-2024)
2 Global Diabetic Neuropathic Pain Drug Market Competition by Company
2.1 Global Top Players by Diabetic Neuropathic Pain Drug Sales (2018-2024)
2.2 Global Top Players by Diabetic Neuropathic Pain Drug Revenue (2018-2024)
2.3 Global Top Players by Diabetic Neuropathic Pain Drug Price (2018-2024)
2.4 Global Top Manufacturers Diabetic Neuropathic Pain Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Diabetic Neuropathic Pain Drug Market Competitive Situation and Trends
2.5.1 Diabetic Neuropathic Pain Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Diabetic Neuropathic Pain Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Diabetic Neuropathic Pain Drug Market
2.8 Key Manufacturers Diabetic Neuropathic Pain Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Diabetic Neuropathic Pain Drug Status and Outlook by Region
3.1 Global Diabetic Neuropathic Pain Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Diabetic Neuropathic Pain Drug Historic Market Size by Region
3.2.1 Global Diabetic Neuropathic Pain Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Diabetic Neuropathic Pain Drug Sales in Value by Region (2018-2024)
3.2.3 Global Diabetic Neuropathic Pain Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Diabetic Neuropathic Pain Drug Forecasted Market Size by Region
3.3.1 Global Diabetic Neuropathic Pain Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Diabetic Neuropathic Pain Drug Sales in Value by Region (2024-2034)
3.3.3 Global Diabetic Neuropathic Pain Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Diabetic Neuropathic Pain Drug by Application
4.1 Diabetic Neuropathic Pain Drug Market Segment by Application
4.1.1 Clinic
4.1.2 Hospital
4.1.3 Others
4.2 Global Diabetic Neuropathic Pain Drug Market Size by Application
4.2.1 Global Diabetic Neuropathic Pain Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Diabetic Neuropathic Pain Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Diabetic Neuropathic Pain Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Diabetic Neuropathic Pain Drug Sales Breakdown by Application (2018-2024)
5 North America Diabetic Neuropathic Pain Drug by Country
5.1 North America Diabetic Neuropathic Pain Drug Historic Market Size by Country
5.1.1 North America Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Diabetic Neuropathic Pain Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Diabetic Neuropathic Pain Drug Sales in Value by Country (2018-2024)
5.2 North America Diabetic Neuropathic Pain Drug Forecasted Market Size by Country
5.2.1 North America Diabetic Neuropathic Pain Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Diabetic Neuropathic Pain Drug Sales in Value by Country (2024-2034)
6 Europe Diabetic Neuropathic Pain Drug by Country
6.1 Europe Diabetic Neuropathic Pain Drug Historic Market Size by Country
6.1.1 Europe Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Diabetic Neuropathic Pain Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Diabetic Neuropathic Pain Drug Sales in Value by Country (2018-2024)
6.2 Europe Diabetic Neuropathic Pain Drug Forecasted Market Size by Country
6.2.1 Europe Diabetic Neuropathic Pain Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Diabetic Neuropathic Pain Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Diabetic Neuropathic Pain Drug by Region
7.1 Asia-Pacific Diabetic Neuropathic Pain Drug Historic Market Size by Region
7.1.1 Asia-Pacific Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Diabetic Neuropathic Pain Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Diabetic Neuropathic Pain Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Diabetic Neuropathic Pain Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Diabetic Neuropathic Pain Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Diabetic Neuropathic Pain Drug Sales in Value by Region (2024-2034)
8 Latin America Diabetic Neuropathic Pain Drug by Country
8.1 Latin America Diabetic Neuropathic Pain Drug Historic Market Size by Country
8.1.1 Latin America Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Diabetic Neuropathic Pain Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Diabetic Neuropathic Pain Drug Sales in Value by Country (2018-2024)
8.2 Latin America Diabetic Neuropathic Pain Drug Forecasted Market Size by Country
8.2.1 Latin America Diabetic Neuropathic Pain Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Diabetic Neuropathic Pain Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Diabetic Neuropathic Pain Drug by Country
9.1 Middle East and Africa Diabetic Neuropathic Pain Drug Historic Market Size by Country
9.1.1 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Diabetic Neuropathic Pain Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Diabetic Neuropathic Pain Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Diabetic Neuropathic Pain Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Diabetic Neuropathic Pain Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Astellas Pharma Inc.
10.1.1 Astellas Pharma Inc. Company Information
10.1.2 Astellas Pharma Inc. Introduction and Business Overview
10.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Products Offered
10.1.5 Astellas Pharma Inc. Recent Development
10.2 AstraZeneca Plc
10.2.1 AstraZeneca Plc Company Information
10.2.2 AstraZeneca Plc Introduction and Business Overview
10.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Products Offered
10.2.5 AstraZeneca Plc Recent Development
10.3 BioDelivery Sciences International, Inc.
10.3.1 BioDelivery Sciences International, Inc. Company Information
10.3.2 BioDelivery Sciences International, Inc. Introduction and Business Overview
10.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Products Offered
10.3.5 BioDelivery Sciences International, Inc. Recent Development
10.4 Boehringer Ingelheim GmbH
10.4.1 Boehringer Ingelheim GmbH Company Information
10.4.2 Boehringer Ingelheim GmbH Introduction and Business Overview
10.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Products Offered
10.4.5 Boehringer Ingelheim GmbH Recent Development
10.5 Daiichi Sankyo Company, Limited
10.5.1 Daiichi Sankyo Company, Limited Company Information
10.5.2 Daiichi Sankyo Company, Limited Introduction and Business Overview
10.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Products Offered
10.5.5 Daiichi Sankyo Company, Limited Recent Development
10.6 Dong-A Socio Group
10.6.1 Dong-A Socio Group Company Information
10.6.2 Dong-A Socio Group Introduction and Business Overview
10.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Products Offered
10.6.5 Dong-A Socio Group Recent Development
10.7 Eli Lilly and Company
10.7.1 Eli Lilly and Company Company Information
10.7.2 Eli Lilly and Company Introduction and Business Overview
10.7.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Products Offered
10.7.5 Eli Lilly and Company Recent Development
10.8 Glenmark Pharmaceuticals Ltd.
10.8.1 Glenmark Pharmaceuticals Ltd. Company Information
10.8.2 Glenmark Pharmaceuticals Ltd. Introduction and Business Overview
10.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Products Offered
10.8.5 Glenmark Pharmaceuticals Ltd. Recent Development
10.9 Hydra Biosciences, Inc.
10.9.1 Hydra Biosciences, Inc. Company Information
10.9.2 Hydra Biosciences, Inc. Introduction and Business Overview
10.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Products Offered
10.9.5 Hydra Biosciences, Inc. Recent Development
10.10 Immune Pharmaceuticals Inc.
10.10.1 Immune Pharmaceuticals Inc. Company Information
10.10.2 Immune Pharmaceuticals Inc. Introduction and Business Overview
10.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Products Offered
10.10.5 Immune Pharmaceuticals Inc. Recent Development
10.11 Laboratorios Del Dr. Esteve S.A.
10.11.1 Laboratorios Del Dr. Esteve S.A. Company Information
10.11.2 Laboratorios Del Dr. Esteve S.A. Introduction and Business Overview
10.11.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Products Offered
10.11.5 Laboratorios Del Dr. Esteve S.A. Recent Development
10.12 Lohocla Research Corporation
10.12.1 Lohocla Research Corporation Company Information
10.12.2 Lohocla Research Corporation Introduction and Business Overview
10.12.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Products Offered
10.12.5 Lohocla Research Corporation Recent Development
10.13 Mertiva AB
10.13.1 Mertiva AB Company Information
10.13.2 Mertiva AB Introduction and Business Overview
10.13.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Mertiva AB Diabetic Neuropathic Pain Drug Products Offered
10.13.5 Mertiva AB Recent Development
10.14 Novaremed
10.14.1 Novaremed Company Information
10.14.2 Novaremed Introduction and Business Overview
10.14.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Novaremed Diabetic Neuropathic Pain Drug Products Offered
10.14.5 Novaremed Recent Development
10.15 Pharmaleads
10.15.1 Pharmaleads Company Information
10.15.2 Pharmaleads Introduction and Business Overview
10.15.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Pharmaleads Diabetic Neuropathic Pain Drug Products Offered
10.15.5 Pharmaleads Recent Development
10.16 RAPID Pharmaceuticals AG
10.16.1 RAPID Pharmaceuticals AG Company Information
10.16.2 RAPID Pharmaceuticals AG Introduction and Business Overview
10.16.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.16.4 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Products Offered
10.16.5 RAPID Pharmaceuticals AG Recent Development
10.17 Relmada Therapeutics, Inc.
10.17.1 Relmada Therapeutics, Inc. Company Information
10.17.2 Relmada Therapeutics, Inc. Introduction and Business Overview
10.17.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.17.4 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Products Offered
10.17.5 Relmada Therapeutics, Inc. Recent Development
10.18 Sphaera Pharma Pvt. Ltd.
10.18.1 Sphaera Pharma Pvt. Ltd. Company Information
10.18.2 Sphaera Pharma Pvt. Ltd. Introduction and Business Overview
10.18.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.18.4 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Products Offered
10.18.5 Sphaera Pharma Pvt. Ltd. Recent Development
10.19 Theravasc, Inc.
10.19.1 Theravasc, Inc. Company Information
10.19.2 Theravasc, Inc. Introduction and Business Overview
10.19.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2018-2024)
10.19.4 Theravasc, Inc. Diabetic Neuropathic Pain Drug Products Offered
10.19.5 Theravasc, Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Diabetic Neuropathic Pain Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Diabetic Neuropathic Pain Drug Industrial Chain Analysis
11.4 Diabetic Neuropathic Pain Drug Market Dynamics
11.4.1 Diabetic Neuropathic Pain Drug Industry Trends
11.4.2 Diabetic Neuropathic Pain Drug Market Drivers
11.4.3 Diabetic Neuropathic Pain Drug Market Challenges
11.4.4 Diabetic Neuropathic Pain Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Diabetic Neuropathic Pain Drug Distributors
12.3 Diabetic Neuropathic Pain Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of AZD-5213
Table 2. Major Company of Clonidine Hydrochloride
Table 3. Major Company of Duloxetine Hydrochloride DR
Table 4. Major Company of E-52862
Table 5. Major Company of Filgrastim
Table 6. Major Company of GERPOOI
Table 7. Major Company of GRC-17536
Table 8. Major Company of Others
Table 9. Global Diabetic Neuropathic Pain Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 10. Global Diabetic Neuropathic Pain Drug Sales by Type (2018-2024) & (K Pcs)
Table 11. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type (2018-2024)
Table 12. Global Diabetic Neuropathic Pain Drug Sales by Type (2018-2024) & (US& Million)
Table 13. Global Diabetic Neuropathic Pain Drug Market Share in Value by Type (2018-2024)
Table 14. Global Diabetic Neuropathic Pain Drug Price by Type (2018-2024) & (USD/Pcs)
Table 15. Global Diabetic Neuropathic Pain Drug Sales by Type (2024-2034) & (K Pcs)
Table 16. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type (2024-2034)
Table 17. Global Diabetic Neuropathic Pain Drug Sales by Type (2024-2034) & (US$ Million)
Table 18. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type (2024-2034)
Table 19. Global Diabetic Neuropathic Pain Drug Price by Type (2024-2034) & (USD/Pcs)
Table 20. North America Diabetic Neuropathic Pain Drug Sales by Type (2018-2024) & (K Pcs)
Table 21. North America Diabetic Neuropathic Pain Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Europe Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2018-2024)
Table 23. Europe Diabetic Neuropathic Pain Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Asia-Pacific Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2018-2024)
Table 25. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Latin America Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2018-2024)
Table 27. Latin America Diabetic Neuropathic Pain Drug Sales by Type (2018-2024) & (US$ Million)
Table 28. Middle East and Africa Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2018-2024)
Table 29. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Type (2018-2024) & (US$ Million)
Table 30. Global Diabetic Neuropathic Pain Drug Sales by Company (2018-2024) & (K Pcs)
Table 31. Global Diabetic Neuropathic Pain Drug Sales Share by Company (2018-2024)
Table 32. Global Diabetic Neuropathic Pain Drug Revenue by Company (2018-2024) & (US$ Million)
Table 33. Global Diabetic Neuropathic Pain Drug Revenue Share by Company (2018-2024)
Table 34. Global Market Diabetic Neuropathic Pain Drug Price by Company (2018-2024) & (USD/Pcs)
Table 35. Global Diabetic Neuropathic Pain Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 36. Global Diabetic Neuropathic Pain Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 37. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2022)
Table 38. Date of Key Manufacturers Enter into Diabetic Neuropathic Pain Drug Market
Table 39. Key Manufacturers Diabetic Neuropathic Pain Drug Product Type
Table 40. Mergers & Acquisitions, Expansion Plans
Table 41. Global Diabetic Neuropathic Pain Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 42. Global Diabetic Neuropathic Pain Drug Sales by Region (2018-2024) & (K Pcs)
Table 43. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Region (2018-2024)
Table 44. Global Diabetic Neuropathic Pain Drug Sales by Region (2018-2024) & (US$ Million)
Table 45. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Region (2018-2024)
Table 46. Global Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 47. Global Diabetic Neuropathic Pain Drug Sales by Region (2024-2034) & (K Pcs)
Table 48. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Region (2024-2034)
Table 49. Global Diabetic Neuropathic Pain Drug Sales by Region (2024-2034) & (US$ Million)
Table 50. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Region (2024-2034)
Table 51. Global Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 52. Global Diabetic Neuropathic Pain Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 53. Global Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) & (K Pcs)
Table 54. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application (2018-2024)
Table 55. Global Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) & (US$ Million)
Table 56. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application (2018-2024)
Table 57. Global Diabetic Neuropathic Pain Drug Price by Application (2018-2024) & (USD/Pcs)
Table 58. Global Diabetic Neuropathic Pain Drug Sales by Application (2024-2034) & (K Pcs)
Table 59. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application (2024-2034)
Table 60. Global Diabetic Neuropathic Pain Drug Sales by Application (2024-2034) & (US$ Million)
Table 61. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application (2024-2034)
Table 62. Global Diabetic Neuropathic Pain Drug Price by Application (2024-2034) & (USD/Pcs)
Table 63. North America Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) (K Pcs)
Table 64. North America Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Europe Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) (K Pcs)
Table 66. Europe Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) (K Pcs)
Table 68. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. Latin America Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) (K Pcs)
Table 70. Latin America Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) & (US$ Million)
Table 71. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) (K Pcs)
Table 72. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Application (2018-2024) & (US$ Million)
Table 73. North America Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (K Pcs)
Table 74. North America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Country (2018-2024)
Table 75. North America Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (US$ Million)
Table 76. North America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Country (2018-2024)
Table 77. North America Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (K Pcs)
Table 78. North America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Country (2024-2034)
Table 79. North America Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (US$ Million)
Table 80. North America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Country (2024-2034)
Table 81. Europe Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (K Pcs)
Table 82. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Country (2018-2024)
Table 83. Europe Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (US$ Million)
Table 84. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Value by Country (2018-2024)
Table 85. Europe Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (K Pcs)
Table 86. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Country (2024-2034)
Table 87. Europe Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (US$ Million)
Table 88. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Value by Country (2024-2034)
Table 89. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Region (2018-2024) & (K Pcs)
Table 90. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Region (2018-2024)
Table 91. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Region (2018-2024) & (US$ Million)
Table 92. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Value by Region (2018-2024)
Table 93. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Region (2024-2034) & (K Pcs)
Table 94. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Region (2024-2034)
Table 95. Asia-Pacific Diabetic Neuropathic Pain Drug Sales by Region (2024-2034) & (US$ Million)
Table 96. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Value by Region (2024-2034)
Table 97. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (K Pcs)
Table 98. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Country (2018-2024)
Table 99. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (US$ Million)
Table 100. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Country (2018-2024)
Table 101. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (K Pcs)
Table 102. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Country (2024-2034)
Table 103. Latin America Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (US$ Million)
Table 104. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Country (2024-2034)
Table 105. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (K Pcs)
Table 106. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Country (2018-2024)
Table 107. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2018-2024) & (US$ Million)
Table 108. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Value by Country (2018-2024)
Table 109. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (K Pcs)
Table 110. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Country (2024-2034)
Table 111. Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2024-2034) & (US$ Million)
Table 112. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Value by Country (2024-2034)
Table 113. Astellas Pharma Inc. Company Information
Table 114. Astellas Pharma Inc. Introduction and Business Overview
Table 115. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 116. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product
Table 117. Astellas Pharma Inc. Recent Development
Table 118. AstraZeneca Plc Company Information
Table 119. AstraZeneca Plc Introduction and Business Overview
Table 120. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 121. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product
Table 122. AstraZeneca Plc Recent Development
Table 123. BioDelivery Sciences International, Inc. Company Information
Table 124. BioDelivery Sciences International, Inc. Introduction and Business Overview
Table 125. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 126. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product
Table 127. BioDelivery Sciences International, Inc. Recent Development
Table 128. Boehringer Ingelheim GmbH Company Information
Table 129. Boehringer Ingelheim GmbH Introduction and Business Overview
Table 130. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 131. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product
Table 132. Boehringer Ingelheim GmbH Recent Development
Table 133. Daiichi Sankyo Company, Limited Company Information
Table 134. Daiichi Sankyo Company, Limited Introduction and Business Overview
Table 135. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 136. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product
Table 137. Daiichi Sankyo Company, Limited Recent Development
Table 138. Dong-A Socio Group Company Information
Table 139. Dong-A Socio Group Introduction and Business Overview
Table 140. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 141. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product
Table 142. Dong-A Socio Group Recent Development
Table 143. Eli Lilly and Company Company Information
Table 144. Eli Lilly and Company Introduction and Business Overview
Table 145. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 146. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product
Table 147. Eli Lilly and Company Recent Development
Table 148. Glenmark Pharmaceuticals Ltd. Company Information
Table 149. Glenmark Pharmaceuticals Ltd. Introduction and Business Overview
Table 150. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 151. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product
Table 152. Glenmark Pharmaceuticals Ltd. Recent Development
Table 153. Hydra Biosciences, Inc. Company Information
Table 154. Hydra Biosciences, Inc. Introduction and Business Overview
Table 155. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 156. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product
Table 157. Hydra Biosciences, Inc. Recent Development
Table 158. Immune Pharmaceuticals Inc. Company Information
Table 159. Immune Pharmaceuticals Inc. Introduction and Business Overview
Table 160. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 161. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product
Table 162. Immune Pharmaceuticals Inc. Recent Development
Table 163. Laboratorios Del Dr. Esteve S.A. Company Information
Table 164. Laboratorios Del Dr. Esteve S.A. Introduction and Business Overview
Table 165. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 166. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product
Table 167. Laboratorios Del Dr. Esteve S.A. Recent Development
Table 168. Lohocla Research Corporation Company Information
Table 169. Lohocla Research Corporation Introduction and Business Overview
Table 170. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 171. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product
Table 172. Lohocla Research Corporation Recent Development
Table 173. Mertiva AB Company Information
Table 174. Mertiva AB Introduction and Business Overview
Table 175. Mertiva AB Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 176. Mertiva AB Diabetic Neuropathic Pain Drug Product
Table 177. Mertiva AB Recent Development
Table 178. Novaremed Company Information
Table 179. Novaremed Introduction and Business Overview
Table 180. Novaremed Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 181. Novaremed Diabetic Neuropathic Pain Drug Product
Table 182. Novaremed Recent Development
Table 183. Pharmaleads Company Information
Table 184. Pharmaleads Introduction and Business Overview
Table 185. Pharmaleads Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 186. Pharmaleads Diabetic Neuropathic Pain Drug Product
Table 187. Pharmaleads Recent Development
Table 188. RAPID Pharmaceuticals AG Company Information
Table 189. RAPID Pharmaceuticals AG Introduction and Business Overview
Table 190. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 191. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product
Table 192. RAPID Pharmaceuticals AG Recent Development
Table 193. Relmada Therapeutics, Inc. Company Information
Table 194. Relmada Therapeutics, Inc. Introduction and Business Overview
Table 195. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 196. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product
Table 197. Relmada Therapeutics, Inc. Recent Development
Table 198. Sphaera Pharma Pvt. Ltd. Company Information
Table 199. Sphaera Pharma Pvt. Ltd. Introduction and Business Overview
Table 200. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 201. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product
Table 202. Sphaera Pharma Pvt. Ltd. Recent Development
Table 203. Theravasc, Inc. Company Information
Table 204. Theravasc, Inc. Introduction and Business Overview
Table 205. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 206. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product
Table 207. Theravasc, Inc. Recent Development
Table 208. Key Raw Materials Lists
Table 209. Raw Materials Key Suppliers Lists
Table 210. Diabetic Neuropathic Pain Drug Market Trends
Table 211. Diabetic Neuropathic Pain Drug Market Drivers
Table 212. Diabetic Neuropathic Pain Drug Market Challenges
Table 213. Diabetic Neuropathic Pain Drug Market Restraints
Table 214. Diabetic Neuropathic Pain Drug Distributors List
Table 215. Diabetic Neuropathic Pain Drug Downstream Customers
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources
List of Figures
Figure 1. Diabetic Neuropathic Pain Drug Product Picture
Figure 2. Global Diabetic Neuropathic Pain Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Diabetic Neuropathic Pain Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Diabetic Neuropathic Pain Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of AZD-5213
Figure 6. Global AZD-5213 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Clonidine Hydrochloride
Figure 8. Global Clonidine Hydrochloride Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of Duloxetine Hydrochloride DR
Figure 10. Global Duloxetine Hydrochloride DR Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of E-52862
Figure 12. Global E-52862 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of Filgrastim
Figure 14. Global Filgrastim Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of GERPOOI
Figure 16. Global GERPOOI Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Product Picture of GRC-17536
Figure 18. Global GRC-17536 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 19. Product Picture of Others
Figure 20. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 21. Global Diabetic Neuropathic Pain Drug Sales by Type (2018-2034) & (US$ Million)
Figure 22. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2022 & 2034
Figure 23. North America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2022
Figure 24. North America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2022
Figure 25. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2022
Figure 26. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2022
Figure 27. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2022
Figure 28. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2022
Figure 29. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2022
Figure 30. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2022
Figure 31. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type in 2022
Figure 32. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type in 2022
Figure 33. The 5 and 10 Largest Manufacturers in the World: Market Share by Diabetic Neuropathic Pain Drug Sales in 2022
Figure 34. The 5 and 10 Largest Manufacturers in the World: Market Share by Diabetic Neuropathic Pain Drug Revenue in 2022
Figure 35. Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 36. Product Picture of Clinic
Figure 37. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Product Picture of Hospital
Figure 39. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 40. Product Picture of Others
Figure 41. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 42. Global Diabetic Neuropathic Pain Drug Sales by Application (2018-2034) & (US$ Million)
Figure 43. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application in 2022 & 2034
Figure 44. North America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application in 2022
Figure 45. North America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2022
Figure 46. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application in 2022
Figure 47. Europe Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2022
Figure 48. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application in 2022
Figure 49. Asia-Pacific Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2022
Figure 50. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application in 2022
Figure 51. Latin America Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2022
Figure 52. Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application in 2022
Figure 53. Key Raw Materials Price
Figure 54. Diabetic Neuropathic Pain Drug Manufacturing Cost Structure
Figure 55. Diabetic Neuropathic Pain Drug Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed